Adjuvant Chemotherapy in Patients with Completely Resected Small Cell Lung Cancer: A Retrospective Analysis of 26 Consecutive Cases

被引：0
作者：
Mizugaki, Hidenori [1 ]
Fujiwara, Yutaka [1 ]
Yamamoto, Noboru [1 ]
Yagishita, Shigehiro [1 ]
Kitazono, Satoru [1 ]
Tanaka, Ayako [1 ]
Horinouchi, Hidehito [1 ]
Kanda, Shintaro [1 ]
Nokihara, Hiroshi [1 ]
Tsuta, Koji [2 ]
Asamura, Hisao [3 ]
Tamura, Tomohide [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Dept Thorac Surg, Tokyo 1040045, Japan
来源：
JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 44卷 / 09期
关键词：
small cell lung cancer; surgery; adjuvant chemotherapy; SURGICAL RESECTION; CARCINOMA; CISPLATIN; ETOPOSIDE; TRIAL;
D O I：
10.1093/jjco/hyu092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: Several clinical studies have demonstrated the efficacy and safety of adjuvant chemotherapy in patients with completely resected small cell lung cancer for a selected limited stage. However, it is unclear whether adjuvant chemotherapy is feasible in clinical practice. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for small cell lung cancer patients retrospectively in clinical practice. Methods: From January 2002 to March 2012, 56 small cell lung cancer patients underwent surgery as initial therapy in our institute. Of these, 26 patients received adjuvant chemotherapy. The clinical data of patients who received adjuvant chemotherapy were retrospectively analyzed. Results: The chemotherapy regimens were cisplatin and irinotecan in 16 patients, cisplatin and etoposide in 1 and carboplatin and etoposide in 9. Median follow-up time was 44.8 months. Nineteen (73%) patients received the full course of chemotherapy. Median recurrence-free survival was 21.4 months. Median survival time was not reached. There was no treatment-related death. Conclusion: Adjuvant chemotherapy may be generally safe and efficacious in selected small cell lung cancer patients.
引用
收藏
页码：835 / 840
页数：6
相关论文
共 50 条
  • [41] Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non-small cell lung cancer invading the chest wall
    Drake, Justin A.
    Sullivan, Jennifer L.
    Weksler, Benny
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (04) : 1794 - 1802
  • [42] Indications for Adjuvant Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer
    Wakeam, Elliot
    Giuliani, Meredith
    Leighl, Natasha B.
    Finlayson, Samuel R. G.
    Varghese, Thomas K.
    Darling, Gail E.
    ANNALS OF THORACIC SURGERY, 2017, 103 (05) : 1647 - 1653
  • [43] Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701
    Soh, Junichi
    Okumura, Norihito
    Nakata, Masao
    Nakamura, Hiroshige
    Fukuda, Minoru
    Kataoka, Masafumi
    Kajiwara, Shinsuke
    Sano, Yoshifumi
    Aoe, Motoi
    Kataoka, Kazuhiko
    Hotta, Katsuyuki
    Matsuo, Keitaro
    Toyooka, Shinichi
    Date, Hiroshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (08) : 741 - 747
  • [44] A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective
    Barlesi, Fabrice
    Chouaid, Christos
    Crequit, Jacky
    Le Caer, Herve
    Pujol, Jean-Louis
    Legodec, Julien
    Vergnenegre, Alain
    Le Treut, Jacques
    Fabre-Guillevin, Elizabeth
    Loundou, Anderson
    Auquier, Pascal
    Simeoni, Marie-Claude
    Thomas, Pascal A.
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2015, 20 (06) : 783 - 790
  • [45] The prognostic factors in the elderly patients with small cell lung cancer: a retrospective analysis from a single cancer institute
    Liu, Sujing
    Guo, Hongbo
    Kong, Li
    Li, Huihui
    Zhang, Yan
    Zhu, Hui
    Yu, Jinming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (09): : 11033 - 11041
  • [46] A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707)
    Kunitoh, Hideo
    Tsuboi, Masahiro
    Wakabayashi, Masashi
    Okada, Morihito
    Suzuki, Kenji
    Watanabe, Shun-ichi
    Asamura, Hisao
    JTCVS OPEN, 2020, 4 : 90 - 102
  • [47] Safety and tolerability of adjuvant platinum and vinorelbine chemotherapy in completely resected early stage non small cell lung cancer patients - single centre review
    Gyi, M. M.
    Gulliford, T.
    Muthuramalingam, S.
    LUNG CANCER, 2012, 75 : S11 - S12
  • [48] A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer
    De Pas, Tommaso
    Raimondi, Sara
    Pelosi, Giuseppe
    Spaggiari, Lorenzo
    De Braud, Fillipo
    Veronesi, Giulia
    Maisonneuve, Patrick
    ACTA ONCOLOGICA, 2010, 49 (04) : 480 - 484
  • [49] Selection for adjuvant chemotherapy in completely resected stage I non-small cell lung cancer: external validation of a Chinese prognostic risk model
    Kumbasar, Ulas
    Raubenheimer, Hilgardt
    Al Sahaf, May
    Asadi, Nizar
    Cufari, Maria Elena
    Proli, Chiara
    Perikleous, Periklis
    Niwaz, Zakiyah
    Beddow, Emma
    Anikin, Vladimir
    McGonigle, Niall
    Jordan, Simon
    Ladas, George
    Dusmet, Michael
    Lim, Eric
    JOURNAL OF THORACIC DISEASE, 2016, 8 (01) : 140 - 144
  • [50] Adjuvant chemotherapy for non small cell lung cancer
    Jankilevich, Gustavo
    MEDICINA-BUENOS AIRES, 2009, 69 (02) : 177 - 180
12345